Navigation Links
Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
Date:10/12/2009

SEATTLE, Oct. 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark and Pedro Granadillo have been elected to the Company's Board of Directors. Mr. Clark is currently head of global product strategy and chief marketing officer at Roche, Pharma Division, and, beginning January 1, 2010, he will be chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group. Mr. Granadillo, now retired, was most recently senior vice president of global manufacturing and human resources at Eli Lilly & Company.

"We are pleased to welcome Ian and Pedro to Dendreon's Board of Directors. Their industry leadership experience commercializing significant oncology products and managing large scale pharmaceutical manufacturing facilities make them ideal additions to our Board of Directors as we expand from a research organization into a commercial enterprise," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Their commercial expertise will strengthen the existing team at Dendreon as we prepare for U.S. Food and Drug Administration approval and the launch of PROVENGE® (sipuleucel-T) next year."

Mr. Clark previously was executive vice president of commercial operations and senior vice president of oncology commercial operations for Genentech's BioOncology business unit, which focused on global commercialization of the company's diverse oncology pipeline, including Avastin®, Rituxan® and Herceptin®. Prior to his time at Genentech, Mr. Clark was president of Novartis Canada and chief operating officer of Novartis United Kingdom. Mr. Clark received a B.S. in biological sciences from Southampton University in the United Kingdom.

Mr. Granadillo worked at Eli Lilly & Company for over thirty years in total, serving in roles such as vice president of human resources, vice president of pharmaceutical manufacturing, executive director of product operations and director of manufacturing strategy development. As the company's top executive for both manufacturing and human resources, Mr. Granadillo was responsible for the overall management of an extensive network of pharmaceutical manufacturing facilities and for policies affecting the company's global workforce of more than 43,000 employees. Mr. Granadillo received a B.S. in industrial engineering from Purdue University. He currently serves on the Board of Directors of Haemonetics Corporation, Nile Therapeutics and Tigris Pharmaceuticals.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

SOURCE Dendreon Corporation


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... January 20, 2017 Stock-Callers.com today evaluates ... SGYP ), Novo Nordisk A/S (NYSE: NVO ... Pernix Therapeutics Holdings Inc. (NASDAQ: PTX ). These ... January 19 th , 2017, finishing near its session lows. ... dropped over 0.7%, while shares of health care companies in ...
(Date:1/20/2017)... , VAE, January 20, 2017 ... gestiegenen Bedarf an Nothilfe   Die internationale humanitäre ... für Hilfsgüter zu schaffen   Seine ... Premierminister der VAE sowie Herrscher von Dubai ... internationalen Stadt der Hilfe (International Humanitarian City IHC) zu ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
Breaking Medicine Technology:
(Date:1/23/2017)... Portland, Oregon (PRWEB) , ... January 23, 2017 ... ... systems, announced today it has earned organic certification under the USDA National Organic ... the USDA Organic Certification process, we have established organic production and handling systems ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events ... is the creation of published author, Charlotte Hotte, a North Carolina native, a mother ... of the book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, ...
(Date:1/23/2017)... ... 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating and ... Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the third ... a preacher for over nineteen, a pastor for over fifteen years. He is a ...
(Date:1/22/2017)... ... January 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated ... met with big-name retail buyers at the January ECRM Trade Show in Hilton Head, ... the utmost safety standards in all of its creations to help create a more ...
Breaking Medicine News(10 mins):